Back to search

University of Patras

Επιγενετική της εξέλιξης και των υποτύπων του μυελοδυσπλαστικού συνδρόμου και φαρμακοεπιγονιδιωματική αιτιολογία της εξατομίκευσης της θεραπείας με απομεθυλιωτικούς παράγοντες

Abstract

dc:description

Myelodysplastic syndromes (MDS) consist of a group of hematological malignanciescharacterized by ineffective hematopoiesis, cytogenetic abnormalities, and often a high171risk of transformation to acute myeloid leukemia (AML). So far, there have been only risk of transformation to acute myeloid leukemia (AML). So far, there have been only a very limited number of studies assessing the epigenetics component contributing to a very limited number of studies assessing the epigenetics component contributing to the pathophysiology of these disorders, but not a single study assessing this at a the pathophysiology of these disorders, but not a single study assessing this at a gengenomeome--wide level. Here, we implemented a generic high throughput epigenomics wide level. Here, we implemented a generic high throughput epigenomics approach, using methylated DNA sequencing (MeDapproach, using methylated DNA sequencing (MeD--seq) of LpnPI digested fragments seq) of LpnPI digested fragments to identify potential epigenomic targets associated with MDS subtypes. Our results to identify potential epigenomic targets associated with MDS subtypes. Our results highlighted that Phighlighted that PCDHG and ZNF gene families harbor potential epigenomic targets, CDHG and ZNF gene families harbor potential epigenomic targets, which have been shown to be differentially methylated in a variety of comparisons which have been shown to be differentially methylated in a variety of comparisons between different MDS subtypes. Specifically, CpG islands, transcription start sites between different MDS subtypes. Specifically, CpG islands, transcription start sites and postand post--transcriptional transcriptional start sites within ZNF124, ZNF497 and PCDHG family are start sites within ZNF124, ZNF497 and PCDHG family are differentially methylated with fold change above 3,5. Overall, these findings highlight differentially methylated with fold change above 3,5. Overall, these findings highlight important aspects of the epigenomic component of MDS syndromes pathogenesis and important aspects of the epigenomic component of MDS syndromes pathogenesis and the pharmacoepigenomic basis to tthe pharmacoepigenomic basis to the hypomethylating agents drug treatment response, he hypomethylating agents drug treatment response, while this generic high throughput whole epigenome sequencing approach could be while this generic high throughput whole epigenome sequencing approach could be readily implemented to other genetic diseases with a strong epigenetic component.readily implemented to other genetic diseases with a strong epigenetic component.

Degree

thesis:*
Grantor dc:publisher
University of Patras
Year dc:date
2023

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Siamoglou, Stavroula
  • Σιαμόγλου, Σταυρούλα

Subjects

dc:subject × 21

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/54932

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Siamoglou, Stavroula; Σιαμόγλου, Σταυρούλα. Επιγενετική της εξέλιξης και των υποτύπων του μυελοδυσπλαστικού συνδρόμου και φαρμακοεπιγονιδιωματική αιτιολογία της εξατομίκευσης της θεραπείας με απομεθυλιωτικούς παράγοντες. University of Patras, 2023. http://hdl.handle.net/10442/hedi/54932